Shingles Shot Shows Short-Term Safety in People With HIV
A recent study found that the herpes zoster vaccine has a favorable short-term safety profile for people living with HIV. Participants showed excellent adherence to the two-dose schedule, with a high completion rate. The study's findings may help reassure patients about the vaccine's safety.
- ▪The study involved 237 participants aged 18 years or older across six centers in Spain.
- ▪82.7% of participants reported adverse events after vaccination, with local pain being the most common.
- ▪No cases of Guillain-Barré syndrome were detected, and adherence to the vaccination schedule was 99.60%.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:The adjuvanted recombinant subunit herpes zoster vaccine showed a favorable short-term safety and tolerability profile in people living with HIV (PLWH), with participants showing excellent adherence to the two-dose schedule.METHODOLOGY:This prospective real-world study monitored vaccination-related adverse events (AEs) after each dose of the adjuvanted recombinant subunit herpes zoster vaccine in PLWH aged 18 years or older.A total of 237 PLWH (84.81% men) received at least one dose of the vaccine across six centers in Spain between June 2022 and February 2024.Participants recorded AEs for 10 days after each dose, along with their duration and any treatments used, and healthcare professionals later reviewed the events through a follow-up phone call.The primary outcome was the…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
